Decades have been witnessing clusters of zoonotic diseases. Human beings at the peak of evolution should not be empowered to alter the environmental homeostasis. Primitive organisms are more rooted to mutate and adapt as per the need or turmoil. Once humans come in the vicinity of these organisms normally residing in their native niche, nature has to pay the cost. Disease outbreaks mostly caused due to unnecessary anthropogenic activities. The threat is that the repercussions are taken for granted or hided wreaking havoc in developing and developed economies leading to an outbreak, an epidemic or a pandemic. The worst influenza outbreak in the world was the 1918 flu that killed nearly 50 million people around the world and modern strains still have an annual death toll in thousands, so the flu is no trifling matter even in a world still facing SARS-CoV-2. Recently, researchers estimated the expected yearly cost of pandemic influenza at roughly $500 billion (0.6 percent of global income), including both lost income and the intrinsic cost of elevated mortality.1

No abstract

No abstract

After the global panic created by COVID-19, the monkeypox (Mpox) virus emerged as a new challenge for the world population. As of 19 January 2023, a total of 84,733 cases across 110 countries/territories including 80 deaths has been reported. The virus has been transmitted to nonendemic countries in a short span of 6 months warranting WHO to declare Mpox, a Public Health Emergency of International Concern on 23 July 2022. As the Mpox virus is crossing geographical boundaries without established transmission patterns, there is an urgent need for new scientific strategies from global researchers to contain it before turning into the next pandemic. The control of Mpox outbreaks primarily relies on various public health measures such as proper surveillance, contact tracing, rapid diagnosis, isolation and care of patients, and vaccination. At present, there are three vaccines viz. ACAM2000, MVABN, and LC16 are in consideration and have been approved in several jurisdictions for ongoing Mpox outbreak. Prioritization of individuals along with the production of specific Mpox vaccine is need of the hour to meet out the global demand of Mpox vaccination.